They did recognize that adults with weakened immune systems and chronic respiratory illnesses are at elevated risk for severe illness.
The vaccine advisory group voted 14 to 1 in favor of lowering the age for pneumococcal vaccination from 65 to 50.
Shingles may contribute to cognitive decline through neuroinflammation, direct neuron injury, or the activation of other herpesviruses, the authors say.
Uptake is even lower in men, Hispanic respondents, and people with less education.
Researchers say the introduction of typhoid conjugate vaccines in these countries could help protect communities, especially school-aged children.
A literature review found pneumococcal conjugate vaccines were associated with some protection against flu and other viral respiratory tract infections.
The experimental vaccine is currently being evaluated in a phase 3 clinical trial in patients aged 60 years and older.
The funding will help the Bacterial Vaccines Network diversify its pipeline of bacterial vaccine development projects.
One study found hospitalization was lower among older adults who received the vaccine, while another found significant racial and socioeconomic disparities in vaccine uptake.
The results of a phase 2 trial show the experimental vaccine, when given to pregnant women, substantially reduced the risk of group B streptococcus infection in their infants.
